Halozyme Therapeutics Inc
NASDAQ: HALO
$60.98
+$1.33 (+2.2%)
Closing Price on November 8, 2024
HALO Stock Chart and Intraday Price
HALO Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Address | 11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 5,213.78M USD |
| Shares Outstanding | 126,825,000 |
HALO Articles
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Published:
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and...
Published:
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Published:
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
Published:
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
Published:
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Published:
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Published:
Last Updated:
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an...
Published:
Last Updated:
As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the new Trump...
Published:
Last Updated:
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
Published:
Last Updated:
These biotech companies stood out from the rest with big moves over the course of the past week.
Published:
Last Updated:
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Published:
Last Updated:
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.
Published:
Wednesday's top analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Monsanto and Virgin America.
Published: